Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

McMurray, J.; Solomon, S.; Inzucchi, S.; Køber, L.; Kosiborod, M.; Martinez, F.; Ponikowski, P.; Sabatine, M.; Anand, I.; Bělohlávek, J.; Böhm, M.; Chiang, C.; Chopra, V.; A. de Boer, Rudolf; S. Desai, Akshay; Diez, M.; Drożdż, J.; Dukát, A.; Ge, J.; Howlett, J.; Katova, T.; Kitakaze, M.; Ljungman, C.; Merkely, B.; Nicolau, J.; O’Meara, E.; Petrie, M.; N. Vinh, P.; Schou, M.; Tereshchenko, S.; Verma, S.; Held, C.; DeMets, D.; Docherty, K.; Jhund, P.; Bengtsson, O.; Sjöstrand, M.; Langkilde, A.; O Ogunniyi, Modele

doi:10.1056/NEJMoa1911303

Public

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Shared by NobleBlocks on Sep 19, 2019 • 12:00 AM UTC

Authors:

J. McMurray

S. Solomon

S. Inzucchi

Abstract

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!